Has Jorge Cruz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,350 in general payments to Jorge Cruz, MD across 233 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jorge Cruz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jorge Cruz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jorge Cruz, MD

General Practice · Slidell, LANPI 1891989380

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.5% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,350in general payments, 2019–2025

Across 233 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$876
AbbVie$742
Novartis$544
LEO Pharma Inc.$345
E.r. Squibb & Sons, L.L.C.$316
Johnson & Johnson$296
plus $1K from 16 others

What the payments were for

Food & beverage$4,24298%
Education$1082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	59	$876
AbbVie	56	$742
Novartis	24	$544
LEO Pharma Inc.	18	$345
E.r. Squibb & Sons, L.L.C.	13	$316
Johnson & Johnson(2 entities)	12	$296
Regeneron Healthcare Solutions, Inc.	11	$275
UCB, Inc.	7	$153
Amgen	7	$128
Lilly USA, LLC	4	$122
Galderma Laboratories, L.p.	2	$105
Sun Pharmaceutical Industries Inc.	4	$71
Cipher Pharmaceuticals US LLC	1	$71
Arcutis Biotherapeutics, Inc.	3	$63
Pfizer	4	$60
Dermavant Sciences, Inc.	1	$39
Medimetriks Pharmaceuticals, Inc.	2	$37
Organon	1	$28
Hill Dermaceuticals, Inc.	1	$27
Phadia US Inc.	1	$20
Biofrontera Inc.	1	$18
Dermira, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

COSENTYX$117
Humira$112

How this compares

$4,350 in reported general payments places this provider in the 95th percentile of 1,221 general practice providers in Louisiana.

See all general practice providers in Louisiana →

Medicare billing

Part B allowed, 2024

$23,963

Medicare patients

Services billed

298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	30	$116,708
Dupixent SyringeDupilumab	23	$87,902
Ketoconazole	197	$2,857
Clobetasol Propionate	97	$2,408
Clindamycin Phosphate	70	$1,442
Tretinoin	18	$1,239
Metronidazole	20	$1,010
Triamcinolone Acetonide	127	$996
Clotrimazole	106	$938
Ammonium Lactate	41	$905
Mupirocin	97	$815
Doxycycline Monohydrate	23	$565
Ciclopirox	19	$476
Fluconazole	32	$176
Doxycycline Hyclate	20	$142

Paid to pharmacies, not to this prescriber.